Problem

Scanbase addresses the difficulty of turning at-home diagnostic tests into dependable, actionable results. Human interpretation of lateral-flow and colorimetric tests can miss faint or low-positive lines, while dried-blood-spot collection can produce inadequate samples and diagnostic errors. The killer use case is a patient photographing a rapid test with a smartphone and receiving a reliable result without relying solely on visual judgment or waiting for a laboratory workflow.

The operational pain extends to diagnostic companies, hospitals, and laboratories: they need faster turnaround, fewer collection and interpretation errors, better visibility into patient results, and modern software that can replace obsolete systems. Scanbase’s proposition is economically attractive because it can deliver immediate results through devices people already own while reducing manual handling and improving the customer experience, although the available evidence does not quantify savings.

Product / Service

Scanbase provides a plug-and-play diagnostic-analysis API that converts photographs of rapid tests into positive or negative results. Its computer-vision and AI algorithms analyze lateral-flow and colorimetric tests, can detect faint positives that may be difficult for the human eye to see, and can verify whether dried-blood-spot cards contain an adequate sample. The API is designed for medical companies to integrate into their own mobile or web applications, with integration described as possible within days.

The delivery model combines API infrastructure with algorithm design and tailored consulting, implementation, and support. Scanbase supports smartphone, tablet, and computer workflows, offers result and sample verification, and has also developed software for laboratory and hospital hardware analyzers. The benefit is a faster path for test manufacturers and healthcare providers to digitize diagnostics, provide near-instant user results, track outcomes in real time, and connect testing to subsequent care.

Market

Scanbase competes in digital-health diagnostics, specifically the software and computer-vision infrastructure layer for at-home rapid tests and decentralized testing. Its buyers are primarily diagnostic-test manufacturers and healthcare organizations that want to add smartphone-based interpretation without building the computer-vision stack themselves. Directly comparable offerings include Abingdon Health’s AppDx smartphone lateral-flow reader, while Safe Health is listed as a broader competitor in third-party market databases.

The company was founded in 2022, joined Y Combinator’s Winter 2023 batch, and is listed as active with a 10-person team. Public product traction includes support for more than 40 lateral-flow and colorimetric tests, compatibility with ADx and Whatman-style dried-blood-spot cards, and expansion into laboratory and hospital analyzers. A third-party estimate reports $3 million of revenue in 2024, but the cited company materials do not name customers or independently verify that figure; the evidence therefore supports viewing Scanbase as a funded, commercial seed-stage company rather than confidently classifying it as pre-revenue.